Management

With more than 25 years of experience in the pharmaceutical and biotechnology industries, particularly in oncology, Fred Vogt has led Iovance through the development, regulatory approvals and commercial launch of Amtagvi^® (lifileucel) for advanced melanoma, the acquisition and integration of Proleukin®, our marketed interleukin-2 (IL-2) product, and construction of our internal manufacturing facility, the Iovance Cell Therapy Center (iCTC), from initial design through pre-approval inspections and capacity expansion. He has built Iovance into a full-scale, international, commercial-stage cell therapy company, augmented the clinical pipeline into new solid tumor indications and advanced our next-generation platform of genetically engineered tumor infiltrating lymphocyte (TIL) and IL-2 therapies. Fred has served as our General Counsel since 2016, our Interim CEO and President since 2021, and a member of our Board of Directors since 2024.

Before joining Iovance, Fred represented life sciences clients in patent strategy, transactions, and litigation at the international law firm Morgan, Lewis & Bockius, with a focus on intellectual property and business law. During 13 years at GlaxoSmithKline, he held research and development, management, and legal roles of increasing responsibility and contributed to the development and approval of multiple successful oncology products, including Hycamtin^®, Votrient^®, Tafinlar^®, Mekinist^®, and Arzerra^®, as well as cardiovascular, antiviral, antibacterial, and metabolic therapies. His experience spans small molecules, proteins, oligonucleotides, antibodies, and cell and gene therapies.

Fred holds a B.S. in Chemistry from Ursinus College, a Ph.D. in Chemistry from Pennsylvania State University, and a J.D. from Temple University. He has authored or co-authored more than 70 research publications and is a co-inventor on more than 20 patent applications. He is admitted to practice in Pennsylvania and before the U.S. Patent and Trademark Office, the U.S. District Court for the Eastern District of Pennsylvania, and the U.S. Court of Appeals for the Federal Circuit.

Corleen Roche is a seasoned public-company Chief Financial Officer (CFO) and corporate financial strategist with more than 30 years in biotech and life sciences. She has deep expertise in capital markets, business development and commercial launch execution.

Corleen joined Iovance in August 2025 as CFO, leading Finance, Accounting, Information Technology, Investor Relations and Financial Strategy as we scale commercial operations, expand manufacturing and advance a broad solid tumor pipeline. She is a strategic partner to the Chief Executive Officer and trusted advisor to the Board. Corleen is squarely focused on driving us to long-term profitability by instilling financial discipline, capturing cost efficiencies and aligning capital allocation with sustainable growth.

Before Iovance, Corleen repeatedly built the financial infrastructure behind pivotal commercial moments at emerging and large biopharma companies. Across her career, she has raised approximately $1 billion in public and private capital. As CFO of CG Oncology, she led an initial public offering and a follow-on offering. As CFO of Immunome, she structured an AbbVie partnership worth up to $2.8 billion. As U.S. CFO at Biogen, Corleen ran finance for its largest commercial organization and helped prepare the launch of a pioneering Alzheimer’s treatment. As CFO of Sandoz Biopharma, she helped introduce Zarxio^®, the first U.S.-approved biosimilar, and Glatopa™, saving $60 million through improved inventory management. As Global CFO of Wyeth’s Vaccines Business Unit, her management of the $4 billion Prevnar^® franchise delivered more than 60 percent revenue and brand profit growth in two years. Prior roles included CFO of CSL Behring North America and senior finance positions at Sanofi.

Corleen holds a B.S. in Accountancy from Villanova University and is a Certified Public Accountant. She began her career at PricewaterhouseCoopers.

Dan Kirby is one of the earliest architects of chimeric antigen receptor T-cell (CAR T) commercial infrastructure in the U.S., with more than two decades of commercial leadership spanning cell therapy, oncology and specialty biologics across strategy, market access and launch execution.

Dan joined Iovance in February 2025 as Chief Commercial Officer, leading global commercial operations for Amtagvi^®, the first cell therapy approved for a solid tumor cancer, and Proleukin^®. Since joining, he has driven the ongoing Amtagvi^® launch with a refocused strategy that deepens physician engagement and accelerates patient access while building our network of treatment centers and field teams to scale adoption. He also leads our international market expansion strategy and product positioning for future launches in non-small cell lung cancer and other solid tumors.

Before Iovance, Dan spent more than four years as Chief Commercial Officer of Orca Bio, a private allogeneic cell therapy company, where he built its commercial, marketing, market access and sales functions. Earlier, as Chief Commercial Officer of Omeros Corporation, he led all commercial functions for Omidria^® and built oncology, hematology and nephrology franchises. Previously, he served as Vice President and Head of U.S. Commercial CAR T at Celgene (now Bristol Myers Squibb) following its acquisition of Juno Therapeutics, where he led marketing and market access for the launch of initial CAR T technology. Prior roles included Head of Marketing at Medivation for Xtandi^®. As Marketing Director for Oncology at Amgen, Dan led U.S. promotion of Neulasta^® and Neupogen^®, Amgen’s top-grossing oncology franchise with more than $5 billion in revenue. His strategies for the Neulasta Onpro launch and the Epogen/Aranesp franchise generated more than $1 billion in additional revenue. During his 14-year tenure, Dan was named Amgen Marketer of the Year in 2014.

Dan holds a B.A. in Business and Communications from the University of Maryland, College Park. He regularly guest lectures as an industry expert at the Harvard Medical School Executive Program.

Igor Bilinsky brings more than 25 years of leadership experience in the biotechnology and life sciences industries, having served as CEO, COO and Chief Business Officer (CBO) at companies advancing novel therapeutics from development through commercialization.

Since joining Iovance as Chief Operating Officer in March 2021, he has overseen the operational execution that brought Amtagvi^® to regulatory approvals and commercial launch for advanced melanoma — the first cell therapy approved by the U.S. Food and Drug Administration (FDA) for a solid tumor. He built and scaled our 136,000-square-foot Iovance Cell Therapy Center in Philadelphia and led the transition of all Amtagvi manufacturing to our internal facility. He oversees operations spanning TIL process and analytical development for new indications and next-generation technologies, manufacturing and global supply chain.

Before Iovance, Igor served as CBO and raised $125 million in equity financing at Oncternal Therapeutics, an oncology company with a first-in-class ROR1 antibody program. As COO of AmpliPhi Biosciences, he led research, development and GMP manufacturing in the U.S., Europe and Australia. At IGNYTA, he established a new immuno-oncology division prior to the $1.7 billion acquisition by Roche and subsequent FDA approval of lead drug entrectinib. At Vical, Igor negotiated and managed partnerships with Astellas, AnGes, Bristol Myers Squibb (BMS) and the Gates Foundation. At Halozyme Therapeutics, he drove out-licensing for the ENHANZE^® platform, now used in marketed products from Roche, Johnson & Johnson, BMS, and Takeda. He also served as CEO of Androclus Therapeutics and Principal at Boston Consulting Group.

Igor holds a B.S. in Physics from the Moscow Institute of Physics and Technology and a Ph.D. in Physics from the Massachusetts Institute of Technology. He is a recipient of Biocom’s James McGraw Distinguished Contribution Award.

Mr. Johnson joined Iovance in August 2015 and was promoted to Chief Business Officer in March 2019. He currently leads corporate development and alliance management. Mr. Johnson is an entrepreneurial executive with more than 30 years of experience in operations, finance, business development, investor relations and venture capital, primarily with bioscience companies. Prior to Iovance, he held executive roles at public and private companies including President and Chief Financial Officer at Vion Pharmaceuticals, an oncology drug development company. He was also a founding investor and initial board member of Acorda Therapeutics. Earlier in his career, Mr. Johnson was an investment banker working on product development financing for leading biotech companies. He received a B.A. from Harvard College and an M.B.A. from Harvard Business School.

Michele Fernandes is a healthcare executive with more than 30 years of global operating experience across multinational pharma and emerging biotech. She brings deep expertise in oncology drug development, clinical operations and portfolio strategy.

Michele joined Iovance in September 2023 as Senior Vice President, Portfolio Management and was promoted to Executive Vice President in December 2025, expanding her role to include Development Operations. Michele’s work translates corporate strategy into disciplined, cross-functional execution while aligning resources, timelines and priorities as we advance tumor infiltrating lymphocyte therapy into new solid tumor indications. She oversees the operational infrastructure behind our late-stage clinical programs in frontline advanced melanoma, non-small cell lung and endometrial cancers as well as advanced soft tissue sarcomas. She also guides early portfolio development for our next-generation products and technologies.

Before Iovance, Michele spent eight years in progressively senior roles at Genentech, culminating as Chief of Staff for Product Development Oncology. She drove portfolio strategy across 23 oncology products and led two large HER2-targeted registration programs to U.S. Food and Drug Administration approval (Kadcyla^® and Perjeta^®). At Acerta Pharma (now AstraZeneca), she served as Vice President of Global Operations and Alliance Management as well as acting Chief Operating Officer. She built and led a 25-person team across the U.S. and EU managing nine external research and development partnerships. At Loxo Oncology, Michele established clinical operations for Vitrakvi^®. At Pfizer, she led a global team of 380 people executing a 27,000-patient cardiovascular endpoint study within a $500 million budget.

Michele holds a B.S. honors degree in Medical Biochemistry from the University of Surrey, UK, a certificate in Organizational Leadership from INSEAD and is a certified Project Management Professional (PMP).

Brian Gastman is a physician-scientist with 18 years in clinical and surgical practice and a National Institutes of Health- and Department of Defense -funded investigator. His contributions to tumor infiltrating lymphocyte (TIL) biology, T cell dysfunction, melanoma and high-risk skin cancers have resulted in multiple patent applications, a licensed asset and best practices for TIL sample procurement.

Brian joined Iovance as Executive Vice President, Medical Affairs in May 2023 and became our Executive Vice President, Translational Medicine and Research in November 2025. Brian has been instrumental in our success across Amtagvi® manufacturing, patient-selection and administration protocols and our network of U.S. Authorized Treatment Centers. Currently, he oversees our early-phase development, investigator-sponsored trials and expanded-access programs.

Before Iovance, Brian grew patient volume by 400% as Co-Medical and Surgical Director of Cleveland Clinic Taussig Cancer Center’s melanoma and skin cancer program. He led investigator-initiated and cooperative-group trials including the largest-ever Phase III Merkel cell carcinoma trial and CheckMate 76K supporting FDA approval of adjuvant nivolumab in stage IIB/C melanoma. He served as Vice Chairman of Plastic Surgery and Professor of Surgery at the Cleveland Clinic Lerner College of Medicine.

Brian founded the Society for Immunotherapy of Cancer’s Surgery Committee and served on the National Comprehensive Cancer Network skin cancer panels. He is a former chair of the Plastic Surgery Research Council, an Associate Editor for the Journal of ImmunoTherapy of Cancer and other journals and author of nearly 200 peer-reviewed publications.

Brian holds an M.D. from the University of Michigan, completed residencies in Otolaryngology and Plastic Surgery at the University of Pittsburgh and fellowship training in head and neck microsurgery at Washington University in St. Louis. He is double-boarded in Plastic Surgery and Otolaryngology.

Raj Puri has unparalleled expertise in tumor infiltrating lymphocyte (TIL) therapy and advanced biologics from more than three decades of leadership experience at the U.S. Food and Drug Administration (FDA), with training under Dr. Steven Rosenberg at the National Cancer Institute’s Surgery Branch and at the Mayo Clinic. His scientific and regulatory background, professional relationships and institutional knowledge give us a distinctive advantage as the field evolves.

Raj joined Iovance in March 2022 as Executive Vice President, Regulatory Strategy and Translational Medicine, and was promoted to Chief Regulatory Officer in November 2024. Under Raj’s leadership, Amtagvi^® became the first cell therapy approved for a solid tumor cancer. He is guiding Amtagvi^® through its post-approval confirmatory program and entry into new markets. He is supporting our pipeline expansion into new indications, including non-small cell lung cancer, soft tissue sarcoma and endometrial cancers, while pioneering the regulatory pathway for our next-generation TIL platform.

Raj spent more than 33 years at the FDA, including more than 19 years as Director of the Division of Cellular and Gene Therapies within the Center for Biologics Evaluation and Research (CBER). He oversaw regulatory programs and shaped the modern regulatory framework for advanced therapies, including cell and gene therapy, cancer vaccines and cellular immunotherapy. Raj led 13 Principal Investigators in his division. As Chief of the Tumor Vaccines and Biotechnology Branch, he established seven Cooperative Research and Development Agreements with industry.

He has published more than 300 research articles, holds numerous licensed patents and has received honors including the FDA Award of Merit, FDA Commissioner’s Special Citations, and the Society for Immunotherapy of Cancer Collaborator Award. He holds an M.D. from the University of Juarez Medical School and a Ph.D. from the Central Drug Research Institute, India.

Mr. Smyth joined Iovance in April 2018 and was appointed Senior Vice President, Quality in 2021. He has 30 years of experience in the pharmaceutical and biopharmaceutical industries. He previously served as Vice President, Regulatory, Quality and Pharmacovigilance at PaxVax, a private-equity company that marketed nine vaccines for infectious diseases in 25 countries. While at PaxVax he was responsible for the Biologics License Application (BLA) submission, priority review and first-cycle approval of Vaxchora^®. Earlier he held roles of increasing responsibility at Baxter International, including as regulatory lead responsible for the development and submission of global market applications for Rixubis^® (US, EU, Japan), now marketed in over 40 countries. Mr. Smyth received a B.S. in Biochemistry from the University of Calgary and an M.S. in Toxicology from the Simon Fraser University (British Columbia).

Tracy Winton is a seasoned human resources (HR) executive with more than 30 years steering people strategy at high-growth, publicly traded life sciences and technology companies, with deep expertise in organizational design, compensation and talent management.

Tracy joined Iovance in April 2020 as Senior Vice President, Human Resources and was promoted to Executive Vice President, Human Resources in July 2024. She leads all people strategy on the Executive Leadership Team, partnering with the Chief Executive Officer, Board and Compensation Committee on executive compensation, equity plan governance and proxy disclosures. She has scaled our organization from roughly 150 to more than 1,000 employees, building the talent infrastructure behind our shift from clinical-stage biotech to commercial operating company with Good Manufacturing Practice manufacturing, clinical development and commercial operations across multiple sites. She also drives workforce planning, succession and recruiting programs to win talent in a competitive market.

Before Iovance, Tracy spent 16 years at Nektar Therapeutics, in progressively senior roles culminating as Vice President, Human Resources. She led all People functions and advised the Board’s Compensation Committee and Executive Team on equity, total rewards, executive compensation and succession planning. She also managed the HR workstream for the divestiture of Nektar’s Pulmonary division to Novartis and directed a site relocation effort that retained more than 80% of targeted employees (above the 25%-50% industry benchmark). Earlier, Tracy designed global sales incentive plans as Senior Director at Sybase, and held compensation leadership roles at Philips Semiconductors North America and Telecom New Zealand.

Tracy holds a B.S. in Anatomy and Microbiology from the University of Otago, a Master’s degree and Diploma of Business Studies in Human Resources Management from Massey University and a Certified Compensation Professional (CCP) designation through WorldatWork.